MedPath

Roche's Vabysmo Gains Reimbursement in China, Eyes Expansion in Asia

• Roche's Vabysmo will be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, covering three ophthalmic indications. • This NRDL listing is expected to significantly enhance Vabysmo's accessibility and market penetration within China. • Roche also announced positive interim results for Vabysmo in treating PCV, potentially broadening its application in Asia.

Roche's Vabysmo, a prominent ophthalmic drug, is set to be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, a move that promises to bolster its presence in the Asian market. This inclusion encompasses three key indications, marking a significant milestone for the drug's accessibility within China.
The announcement, made on November 28, signals a major step forward for Roche in making Vabysmo available to a broader patient population in China. The NRDL listing ensures that the drug will be covered by national health insurance, substantially reducing the financial burden on patients.
In addition to the NRDL listing, Roche has reported positive interim results for Vabysmo in the treatment of polypoidal choroidal vasculopathy (PCV). These findings could pave the way for expanded use of Vabysmo across Asia, addressing a critical unmet need in the region.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Chinese Firms Expand Solo Global Phase III Activity Including US Sites

In 2024, Chinese companies have initiated seven global Phase III trials, including sites in the US, with BeiGene, Genfleet, and InnoCare planning to add four more studies.

China NMPA Approves Astellas' Zolbetuximab for Advanced Gastric and GEJ Adenocarcinoma

China's NMPA has approved zolbetuximab (VYLOY™) for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Zolbetuximab is the first monoclonal antibody approved in China that targets the CLDN18.2 biomarker expressed in gastric tumor cells.

Simcere's Sublingual Edaravone Poised for Global Phase III Trial Following China Approval for Acute Ischemic Stroke

Simcere's sublingual edaravone/dexborneol, Sanbexin, has received approval in China for treating acute ischemic stroke, marking a significant advancement in stroke therapy.
Clinical data indicates that Sanbexin sublingual improved functional outcomes in acute ischemic stroke patients by approximately 10% at day 90.

Nicox's NCX 470 Phase 3 Glaucoma Trial Fully Enrolled in China Ahead of Schedule

Nicox SA announced its Denali Phase 3 trial of NCX 470 for open-angle glaucoma or ocular hypertension is fully enrolled in China, accelerating the overall trial timeline.
The Denali trial evaluates the efficacy and safety of NCX 470 ophthalmic solution compared to latanoprost, with topline results expected in Q3 2025.

Everest Medicines' VELSIPITY® (Etrasimod) Gains Regulatory Traction in Greater China for Ulcerative Colitis Treatment

Everest Medicines' VELSIPITY® (etrasimod) NDA has been accepted in Hong Kong for treating moderately to severely active ulcerative colitis in adults.
VELSIPITY® has already been approved in Macau and implemented in the Greater Bay Area via the 'Hong Kong and Macau Medicine and Equipment Connect' policy.

XPOVIO® (Selinexor) Included in China's National Reimbursement Drug List for R/R DLBCL

Antengene's XPOVIO® (selinexor) gains NRDL inclusion in China for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) post two or more systemic therapies.
This marks XPOVIO®'s second indication in China to be included in the NRDL, enhancing patient access to this innovative treatment option.

Ruxolitinib Cream Prescriptions for Vitiligo Issued in Greater Bay Area, China; NDA Accepted by NMPA

China Medical System Holdings (CMS) announces the first prescriptions of ruxolitinib cream for vitiligo in the Greater Bay Area.
The prescriptions were issued at designated hospitals following approval via the "Hong Kong and Macau Medicine and Equipment Connect" policy.

Nicox's ZERVIATE Approved in China for Allergic Conjunctivitis

Ocumension Therapeutics, Nicox's partner, has received approval in China to commercialize ZERVIATE for treating ocular itching linked to allergic conjunctivitis.
The approval of ZERVIATE marks the first cetirizine ophthalmic solution available in China, addressing a significant gap in treatment options for allergic conjunctivitis.

Chugai Seeks Approval in Japan for Vabysmo to Treat Angioid Streaks

Chugai Pharmaceutical has filed for an additional indication in Japan for Vabysmo to treat angioid streaks associated with neovascularization.
The application is based on positive results from the Phase III NIHONBASHI study, which demonstrated vision improvement in patients.

Bayer Seeks Expanded Approval for Darolutamide in Japan and China for Metastatic Hormone-Sensitive Prostate Cancer

Bayer has submitted applications in Japan and China for darolutamide, seeking approval for metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (ADT).
The submissions are based on the Phase III ARASENS trial, which demonstrated a statistically significant improvement in overall survival for darolutamide plus ADT and docetaxel in mHSPC patients.

Reference News

[1]
Vabysmo Hopes To Ride New Coverage In China, Data To Expand In Asia - Citeline
insights.citeline.com · Nov 29, 2024

Roche's Vabysmo included in China's NRDL for 2025-2026 in three indications, with positive interim results in PCV.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy